How did the Healthtrust merger affect Columbia/HCA's 1995 financial results?

The Healthtrust merger, completed April 24, 1995, was accounted for as a pooling of interests, so prior periods were restated to include Healthtrust. The merger drove much of the 21.7% revenue increase and cost $105 million in merger-related charges, plus $282 million of asset writedowns tied to consolidating duplicative facilities. Those charges reduced reported EPS by $0.53.

What is the company's exposure to government reimbursement?

Medicare accounted for 36% of 1995 patient revenues and Medicaid for 6%, so about 42% of revenue depends on government programs. Medicare pays under a prospective payment system based on diagnosis related groups, and DRG updates have lagged cost inflation. The 10-K expects Medicare prospective payment increases to average about 2% in 1996, which limits the company's ability to offset cost pressure through price increases.

What are the main tax and legal risks disclosed in the filing?

The IRS is contesting roughly $600 million in additional taxes and interest for prior years, including 1981-1991 issues that are in Tax Court or the Court of Federal Claims. A March 1996 Tax Court ruling favored the company on the cash-method issue. A qui tam suit under the False Claims Act alleges improper physician referral payments and seeks treble damages. Management believes these outcomes will not have a material adverse effect, but says an adverse result on most IRS positions could materially hurt results.

How is the company funding its growth and acquisitions?

In 1995 the company spent about $1.5 billion on capital expenditures, $1.3 billion on acquisitions, and $609 million on investments in affiliates. Operating cash flow of $2.25 billion covered only part of that, so the gap was filled with new long-term debt and commercial paper. Total debt reached $7.4 billion at year-end 1995, and the company amended its revolving credit facilities to $4.0 billion in early 1996, with about $1.0 billion available as of February 29, 1996.

Are there any significant risks related to physician ownership arrangements?

Yes. The company's strategy relies on physician co-ownership of facilities, but some of these joint ventures do not meet current federal safe harbor criteria under the anti-kickback statute. The filing also notes Stark II rules that took effect January 1, 1995, and the 10-K says the company cannot predict their final regulatory effect. Federal regulators are also investigating certain financial arrangements with physicians at two psychiatric hospitals. Joint venture partners also hold put rights that could strain liquidity if exercised together.

HCA 10-K FY1995 Annual Report — Revenue, Net Income, EPS

01—Abstract

Summary

Summary of the 10-K filed April 1, 1996. Cited figures are marked; the original filing is the authoritative source.

Columbia/HCA Healthcare's 1995 10-K shows a company that grew revenue sharply through acquisitions, led by the Healthtrust merger, while absorbing large one-time charges.

Revenues rose 21.7% to $17.7 billion, and net income climbed to $961 million^a ($2.14 per share) from $814 million. Excluding merger and facility consolidation costs of $387 million, income from continuing operations was $1.3 billion ($2.90 per share), up 26%. Pretax margin before those charges improved to 12.3% from 11.7%, helped by lower salaries and supply costs as a share of revenue, though other operating expenses rose to 19.4% of revenue.

Operating cash flow reached $2.25 billion^b, but the company spent heavily on acquisitions and capital projects, pushing long-term debt to $7.4 billion and funding the gap with borrowings. The main risks for investors are regulatory and legal. Medicare and Medicaid make up 42% of patient revenue, and the company faces pending IRS claims of roughly $600 million, a False Claims Act qui tam suit, and reimbursement pressure from the Balanced Budget framework and PPS changes.

The company also disclosed a $60 million^c tentative settlement in the MCA securities class action and ongoing ERISA exposure tied to the Healthtrust ESOP. Management says these matters should not have a material adverse effect, but it acknowledges that a broad adverse IRS outcome could materially hurt results.

For investors, the filing reflects a company executing an aggressive consolidation strategy with strong top-line growth and improving underlying margins. The key questions are whether the company can keep integrating acquisitions and sustain margin gains while handling significant debt, tax disputes, and ongoing healthcare reform uncertainty.

02—Key points

Key Highlights

Revenues grew 21.7% to $17.7 billion in 1995, driven mainly by acquisitions including Healthtrust and EPIC, plus same-hospital revenue growth of 10.2%.
Reported net income rose to $961 million ($2.14 per share) from $814 million, but results were held down by $387 million of merger and facility consolidation costs.
Excluding those charges, income from continuing operations was $1.3 billion ($2.90 per share), up 26% from $2.40 per share in 1994.
Pretax margin excluding special charges improved to 12.3% from 11.7%, as salaries and benefits fell to 40.1% of revenue and supply costs fell to 14.5%.
The company operates 319 hospitals and more than 130 outpatient surgery centers, with 62,936 licensed beds at general acute care hospitals and 2,866 at psychiatric hospitals.
Long-term debt increased to $7.4 billion, and the company plans $1.7 billion of capital expenditures for 1996.
Major legal and tax exposures include about $600 million in disputed IRS claims, a False Claims Act qui tam suit, and a tentative $60 million settlement in the MCA securities class action.

03—Questions

Frequently Asked Questions

How did the Healthtrust merger affect Columbia/HCA's 1995 financial results?
The Healthtrust merger, completed April 24, 1995, was accounted for as a pooling of interests, so prior periods were restated to include Healthtrust. The merger drove much of the 21.7% revenue increase and cost $105 million in merger-related charges, plus $282 million of asset writedowns tied to consolidating duplicative facilities. Those charges reduced reported EPS by $0.53.
What is the company's exposure to government reimbursement?
Medicare accounted for 36% of 1995 patient revenues and Medicaid for 6%, so about 42% of revenue depends on government programs. Medicare pays under a prospective payment system based on diagnosis related groups, and DRG updates have lagged cost inflation. The 10-K expects Medicare prospective payment increases to average about 2% in 1996, which limits the company's ability to offset cost pressure through price increases.
What are the main tax and legal risks disclosed in the filing?
The IRS is contesting roughly $600 million in additional taxes and interest for prior years, including 1981-1991 issues that are in Tax Court or the Court of Federal Claims. A March 1996 Tax Court ruling favored the company on the cash-method issue. A qui tam suit under the False Claims Act alleges improper physician referral payments and seeks treble damages. Management believes these outcomes will not have a material adverse effect, but says an adverse result on most IRS positions could materially hurt results.
How is the company funding its growth and acquisitions?
In 1995 the company spent about $1.5 billion on capital expenditures, $1.3 billion on acquisitions, and $609 million on investments in affiliates. Operating cash flow of $2.25 billion covered only part of that, so the gap was filled with new long-term debt and commercial paper. Total debt reached $7.4 billion at year-end 1995, and the company amended its revolving credit facilities to $4.0 billion in early 1996, with about $1.0 billion available as of February 29, 1996.
Are there any significant risks related to physician ownership arrangements?
Yes. The company's strategy relies on physician co-ownership of facilities, but some of these joint ventures do not meet current federal safe harbor criteria under the anti-kickback statute. The filing also notes Stark II rules that took effect January 1, 1995, and the 10-K says the company cannot predict their final regulatory effect. Federal regulators are also investigating certain financial arrangements with physicians at two psychiatric hospitals. Joint venture partners also hold put rights that could strain liquidity if exercised together.

04—Continue

← View all 10-K filings